Updates in diagnosis, treatment, and prevention of anaphylaxis to neuromuscular blocking agents and their antagonists
10.3760/cma.j.cn112150-20220330-00303
- VernacularTitle:神经肌肉阻滞剂及其拮抗剂严重过敏反应的诊治与预防的研究进展
- Author:
Zixi WANG
1
;
Xu LI
;
Xiuhua ZHANG
;
Kai GUAN
Author Information
1. 中国医学科学院北京协和医学院北京协和医院变态反应科，过敏性疾病精准诊疗研究北京市重点实验室，北京 100730
- Keywords:
Neuromuscular blocking agents;
Neuromuscular blocking agents antagonists;
Sugammadex;
Perioperative period;
Anaphylaxis
- From:
Chinese Journal of Preventive Medicine
2022;56(6):740-747
- CountryChina
- Language:Chinese
-
Abstract:
Anaphylaxis to perioperative drugs has an insidious and rapid onset, can be life-threatening, and often results in the suspension of surgery. Neuromuscular blocking agents (NMBAs) are currently considered to be the most common cause of anaphylactic reactions among anesthetic drugs. With the increasing amount of anesthesia and surgery in the world, there are more and more NMBAs use, and the corresponding allergic risk is also increasing. With the use of NMBAs, their antagonists, such as neostigmine and sugammadex, are often used too, which have more and more allergy reports in clinical practice. Due to the complex mechanism of allergy caused by NMBAs and their antagonists, it is difficult to find out the culprit drug. The cross-reactivity between NMBAs is common, so it is often difficult to choose alternative drugs. This article summarized the epidemiology, pathological mechanisms, diagnostic methods and procedures, immediate treatment, and prevention strategies of anaphylaxis caused by these drugs.
